SMMT – Summit Therapeutics Inc
Summit Therapeutics Inc.SMMT
$17.30Name : Summit Therapeutics Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $13,835,915,264.00
EPSttm : -1.06
Summit Therapeutics Inc.
$17.30
2.98%$0.53
SMMT — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
26.86
Margin Of Safety %
Put/Call OI Ratio
0.58
EPS Next Q Diff
0.04
EPS Last/This Y
-0.33
EPS This/Next Y
Price
17.83
Target Price
29.99
Analyst Recom
1.59
Performance Q
18.08
Upside
-178.0%
Beta
-1.52
Ticker: SMMT
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-10-12 | SMMT | 17.14 | 0.70 | 0.20 | 210006 |
| 2026-10-13 | SMMT | 15.53 | 0.69 | 0.25 | 213441 |
| 2026-10-14 | SMMT | 15.12 | 0.65 | 0.17 | 230321 |
| 2026-10-15 | SMMT | 15.36 | 0.62 | 0.53 | 239018 |
| 2026-10-16 | SMMT | 14.65 | 0.61 | 0.47 | 239631 |
| 2026-10-19 | SMMT | 15.59 | 0.62 | 0.39 | 207964 |
| 2026-10-20 | SMMT | 16.1 | 0.62 | 0.28 | 219835 |
| 2026-10-21 | SMMT | 15.82 | 0.61 | 1.14 | 224400 |
| 2026-10-22 | SMMT | 15.56 | 0.62 | 1.04 | 227952 |
| 2026-10-23 | SMMT | 15.47 | 0.63 | 0.26 | 230128 |
| 2026-10-26 | SMMT | 14.51 | 0.63 | 0.34 | 228359 |
| 2026-10-27 | SMMT | 15.34 | 0.64 | 0.43 | 232829 |
| 2026-10-28 | SMMT | 15.78 | 0.64 | 0.40 | 235662 |
| 2026-10-29 | SMMT | 16.2 | 0.63 | 0.10 | 236143 |
| 2026-10-30 | SMMT | 16.02 | 0.60 | 0.03 | 243775 |
| 2026-11-02 | SMMT | 14.8 | 0.56 | 0.24 | 243261 |
| 2026-11-03 | SMMT | 15.78 | 0.56 | 0.26 | 247888 |
| 2026-11-04 | SMMT | 16.18 | 0.56 | 0.16 | 251010 |
| 2026-11-05 | SMMT | 14.18 | 0.55 | 1.59 | 256873 |
| 2026-11-06 | SMMT | 16.34 | 0.64 | 0.32 | 272167 |
| 2026-11-09 | SMMT | 17.84 | 0.57 | 0.37 | 260348 |
| 2026-11-10 | SMMT | 17.82 | 0.58 | 0.56 | 265869 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-10-12 | SMMT | 17.15 | 7.4 | - | -0.85 |
| 2026-10-13 | SMMT | 15.53 | 7.4 | - | -0.85 |
| 2026-10-14 | SMMT | 15.12 | 7.4 | - | -0.85 |
| 2026-10-15 | SMMT | 15.36 | 9.8 | - | -0.84 |
| 2026-10-16 | SMMT | 14.65 | 9.8 | - | -0.84 |
| 2026-10-19 | SMMT | 15.58 | 9.8 | - | -0.84 |
| 2026-10-20 | SMMT | 15.58 | 9.8 | - | -0.84 |
| 2026-10-21 | SMMT | 16.09 | 9.7 | - | -0.84 |
| 2026-10-22 | SMMT | 15.56 | 9.7 | - | -0.84 |
| 2026-10-23 | SMMT | 15.46 | 9.7 | - | -0.84 |
| 2026-10-26 | SMMT | 14.51 | 9.7 | - | -0.84 |
| 2026-10-27 | SMMT | 15.34 | 9.8 | - | -0.84 |
| 2026-10-28 | SMMT | 15.78 | 9.8 | - | -0.84 |
| 2026-10-29 | SMMT | 16.21 | 10.1 | - | -0.84 |
| 2026-10-30 | SMMT | 16.03 | 10.1 | - | -0.84 |
| 2026-11-02 | SMMT | 14.79 | 10.1 | - | -0.84 |
| 2026-11-03 | SMMT | 15.80 | 10.1 | - | -0.84 |
| 2026-11-04 | SMMT | 16.18 | 10.1 | - | -0.84 |
| 2026-11-05 | SMMT | 14.18 | 10.1 | - | -0.84 |
| 2026-11-06 | SMMT | 16.34 | -20.2 | - | -0.84 |
| 2026-11-09 | SMMT | 17.84 | -20.2 | - | -0.84 |
| 2026-11-10 | SMMT | 17.83 | -1.8 | - | -0.79 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-10-12 | SMMT | 1.23 | 12.32 | 27.02 |
| 2026-10-13 | SMMT | 1.23 | 12.32 | 27.02 |
| 2026-10-14 | SMMT | 1.23 | 12.32 | 27.02 |
| 2026-10-15 | SMMT | 1.23 | 12.32 | 27.02 |
| 2026-10-16 | SMMT | 1.23 | 12.32 | 27.02 |
| 2026-10-19 | SMMT | 1.23 | 12.42 | 27.02 |
| 2026-10-20 | SMMT | 1.23 | 12.42 | 27.03 |
| 2026-10-21 | SMMT | 1.23 | 12.42 | 27.03 |
| 2026-10-22 | SMMT | 1.23 | 12.42 | 27.03 |
| 2026-10-23 | SMMT | 1.23 | 12.42 | 27.03 |
| 2026-10-26 | SMMT | 1.23 | 12.55 | 27.03 |
| 2026-10-27 | SMMT | 1.23 | 12.55 | 26.86 |
| 2026-10-28 | SMMT | 1.23 | 12.55 | 26.86 |
| 2026-10-29 | SMMT | 1.23 | 12.55 | 26.86 |
| 2026-10-30 | SMMT | 1.23 | 12.55 | 26.86 |
| 2026-11-02 | SMMT | 1.23 | 12.71 | 26.86 |
| 2026-11-03 | SMMT | 1.23 | 12.71 | 26.86 |
| 2026-11-05 | SMMT | 1.23 | 12.71 | 26.86 |
| 2026-11-06 | SMMT | 1.23 | 12.71 | 26.86 |
| 2026-11-09 | SMMT | 1.23 | 10.15 | 26.86 |
| 2026-11-10 | SMMT | 1.23 | 10.15 | 26.86 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.26
Avg. EPS Est. Current Quarter
-0.22
Avg. EPS Est. Next Quarter
-0.22
Insider Transactions
1.23
Institutional Transactions
10.15
Beta
-1.52
Average Sales Estimate Current Quarter
1
Average Sales Estimate Next Quarter
5
Fair Value
Quality Score
7
Growth Score
22
Sentiment Score
94
Actual DrawDown %
51.7
Max Drawdown 5-Year %
-87.6
Target Price
29.99
P/E
Forward P/E
PEG
P/S
P/B
25.25
P/Free Cash Flow
EPS
-1.07
Average EPS Est. Cur. Y
-0.79
EPS Next Y. (Est.)
-0.79
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
Relative Volume
0.72
Return on Equity vs Sector %
-100
Return on Equity vs Industry %
-100
EPS 1 7Days Diff
EPS 1 30Days Diff
0.06
EBIT Estimation
◆
SMMT
Healthcare
$17.83
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
58.7
Range 1M
87.9%
Sup Dist
8.1%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
26.9%
EPS NY
3.9%
52W%
32.6%
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+68.2% upside
Upside
+68.2%
Quality
7
SMMT — P/E HistoricalBiotechnology
Summit Therapeutics Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 265
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC). The company has also combined ivonescimab with chemotherapy, which is in phase III clinical trial for the patients with epidermal growth factor receptor, mutated, and locally advanced or metastatic non-squamous NSCLC; first-line metastatic NSCLC; and first-line unresectable metastatic CRC. It markets its products in the United states, Canada, Europe, Japan, Latin America, Middle East, and Africa. The company was founded in 2003 and is headquartered in Miami, Florida.
SMMT
Latest News
—
Caricamento notizie per SMMT…
stock quote shares SMMT – Summit Therapeutics Inc Stock Price stock today
news today SMMT – Summit Therapeutics Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch SMMT – Summit Therapeutics Inc yahoo finance google finance
stock history SMMT – Summit Therapeutics Inc invest stock market
stock prices SMMT premarket after hours
ticker SMMT fair value insiders trading